Table 2. Comparison of the effects of cardioprotective drugs used in this study on cell index, cell viability and MCL-1 expression of cardiomyocytes.
| Drugs and doses | Targets | CI (HL-1) | Viability (%) | MCL-1 (%) | ||
|---|---|---|---|---|---|---|
| HL-1 | hCAVSMC | HL-1 | hCAVSMC | |||
| Values compared to untreated | ||||||
| Nebivolol, 3μM | β1 AR; β3 AR | Lower, with dip | *96% | *96% | # 71% | # 87% |
| Carvedilol, 3μM | β1 and β2 AR | Lower, with dip | *93% | *98% | # 75% | *92% |
| Metoprolol, 3μM | β1 and β2 AR | Lower | *93% | -- | # 68% | # 80% |
| Atenolol, 3μM | β1 and β2 AR | Lower | *104% | *100% | # 64% | # 64% |
| Ang II 300nM | AT1R & AT2R | Higher | *110% | -- | -- | -- |
| CGP42112A, 300nM | AT2R | Higher | *107% | # 114% | *95% | -- |
| NP-6A4, 300nM | AT2R | Highest | # 120% | # 120% | # 125% | # 123% |
*Not statistically significant
#p<0.05